Showing 641 - 660 results of 668 for search '"Inflammatory Bowel Diseases"', query time: 0.09s Refine Results
  1. 641

    Usefulness of Routine Terminal Ileoscopy and Biopsy during Colonoscopy in a Tropical Setting: A Retrospective Record-Based Study by Hasitha Srimal Wijewantha, Arjuna Priyadarsin de Silva, Madunil Anuk Niriella, Nethini Wijesinghe, Prabahvi Waraketiya, Ravindu Sujeewa Kumarasena, Anuradha Supun Dassanayake, Janaki de Silva Hewawisenthi, Hithanadura Janaka de Silva

    Published 2014-01-01
    “…Patients with right iliac fossa (RIF) pain, diarrhoea, anaemia, suspected inflammatory bowel disease (IBD), and raised inflammatory markers were defined as Group A and all others undergoing colonoscopy as Group B. …”
    Get full text
    Article
  2. 642
  3. 643
  4. 644

    The immunoregulatory effects of scoparone on immune-mediated inflammatory diseases by Feifei Qiu, Jingru Lin, Xiaofei Huang, Bin Yang, Weihui Lu, Weihui Lu, Zhenhua Dai, Zhenhua Dai

    Published 2025-01-01
    “…Therefore, this review not only summarizes the immunomodulatory and therapeutic effects of SCO on immune-based inflammatory diseases (IMIDs), such as inflammatory bowel disease, osteoarthritis, allergic rhinitis, acute lung injury, type 1 diabetes and neuroinflammatory diseases etc., but also provides a comprehensive summary of its therapeutic effects on hepatic diseases, including non-alcoholic steatohepatitis, fulminant hepatic failure and hepatic fibrosis. …”
    Get full text
    Article
  5. 645

    Identification and characterization of Faecalibacterium prophages rich in diversity-generating retroelements by Anastasia Gulyaeva, Lei Liu, Sanzhima Garmaeva, Marloes Kruk, Rinse K. Weersma, Hermie J. M. Harmsen, Alexandra Zhernakova

    Published 2025-02-01
    “…Finally, we noted that four phages were less prevalent in the metagenomes of inflammatory bowel disease patients compared to a general population cohort, a difference mainly explained by differences in the abundance of the host bacteria. …”
    Get full text
    Article
  6. 646

    Multimedia: multimodal mediation analysis of microbiome data by Hanying Jiang, Xinran Miao, Margaret W. Thairu, Mara Beebe, Dan W. Grupe, Richard J. Davidson, Jo Handelsman, Kris Sankaran

    Published 2025-02-01
    “…The first re-analyzes a study of the microbiome and metabolome of Inflammatory Bowel Disease patients, uncovering potential mechanistic interactions between the microbiome and disease-associated metabolites, not found in the original study. …”
    Get full text
    Article
  7. 647

    Brodalumab: Six-Year US Pharmacovigilance Report by Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, Soo Han Yoon, Nicole N. Rawnsley, Earl L. Goehring, Gina D. Mangin, Abby A. Jacobson

    Published 2024-11-01
    “…One new case of indeterminate inflammatory bowel disease unrelated to brodalumab was reported. …”
    Get full text
    Article
  8. 648

    Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients by Constanze Heike Waggershauser, Cornelia Tillack-Schreiber, Paul Weyh, Eckard Alt, Thorsten Siegmund, Christine Berchthold-Benchieb, Daniel Szokodi, Fabian Schnitzler, Thomas Ochsenkühn

    Published 2022-01-01
    “…This study is focused on the question whether patients with inflammatory bowel disease (IBD) who receive immunotherapies are more vulnerable to respiratory tract infections and SARS-CoV-2 infections in comparison to medical staff, as a cohort with an increased infection risk, and to the general population in a COVID-19 hotspot. …”
    Get full text
    Article
  9. 649
  10. 650

    Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD by Katarzyna Neubauer, Malgorzata Matusiewicz, Iwona Bednarz-Misa, Sabina Gorska, Andrzej Gamian, Malgorzata Krzystek-Korpacka

    Published 2018-01-01
    “…Despite the acknowledged contribution of eosinophils to the disease pathogenesis, available data on cytokines closely related to the peripheral eosinophils in inflammatory bowel disease (IBD) are scattered. We assessed the concentrations of eosinophil-associated cytokines and growth factors in the group of 277 individuals (101 patients with Crohn’s disease (CD), 77 with ulcerative colitis (UC), 16 with irritable bowel syndrome (IBS), and 83 healthy controls) and referred to IBD activity and the levels of hsCRP. …”
    Get full text
    Article
  11. 651

    Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life by P. B. Jeppesen, P. Lund, I. B. Gottschalck, H. B. Nielsen, J. J. Holst, J. Mortensen, S. S. Poulsen, B. Quistorff, P. B. Mortensen

    Published 2009-01-01
    “…The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. …”
    Get full text
    Article
  12. 652
  13. 653

    Quinazolinone Derivative MR2938 Protects DSS-Induced Barrier Dysfunction in Mice Through Regulating Gut Microbiota by Ling Lv, Mireguli Maimaitiming, Jichen Yang, Shuli Xia, Xin Li, Pingyuan Wang, Zhiqing Liu, Chang-Yun Wang

    Published 2025-01-01
    “…<b>Background/Objectives</b>: Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by colorectal immune infiltration and significant microbiota compositional changes. …”
    Get full text
    Article
  14. 654

    Arthralgia and Extraintestinal Manifestations in Crohn’s Disease Elevate the Risk of IBD-Related Arthritis over Sacroiliitis by Ivan Giovannini, Nicola Cabas, Marco Marino, Annarita Tullio, Ilaria Tinazzi, Angela Variola, Carmelo Cicciò, Fabro Cinzia, Berretti Debora, Chiara Zuiani, Rossano Girometti, Luca Quartuccio, Alen Zabotti, Lorenzo Cereser

    Published 2024-12-01
    “…Abstract Introduction Inflammatory bowel disease (IBD) related arthritis is the most prevalent extraintestinal manifestation (EIM) of IBD, ranging between 10 and 39%. …”
    Get full text
    Article
  15. 655

    Dual Role of &alpha;-MSH in Colitis Progression: Mediating Neutrophil Differentiation via Bone Marrow by Liao X, Liu H, Li Y, Zhang W, Dai Q, Wei H, Zhou J, Xie X, Zhou H

    Published 2025-02-01
    “…Xiping Liao,1,2 Hengqian Liu,3 Yuanyuan Li,1,4 Wei Zhang,1 Qian Dai,1 Haoqi Wei,5 Jianyun Zhou,1 Xia Xie,2 Hongli Zhou1 1Clinical Medical Research Center, The Second Affiliated Hospital, Army Medical University, Chongqing, People’s Republic of China; 2Department of Gastroenterology, The Second Affiliated Hospital, Army Medical University, Chongqing, People’s Republic of China; 3School of Medicine, Chongqing University, Chongqing, People’s Republic of China; 4Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People’s Republic of China, Chongqing, People’s Republic of China; 5Department of General Surgery, The PLA 77th Group Army Hospital, Leshan City, People’s Republic of ChinaCorrespondence: Xia Xie, Department of Gastroenterology, The Second Affiliated Hospital, Army Medical University, No. 83 Xinqiao Main Street, Shapingba District, Chongqing, 400037, People’s Republic of China, Email xiexia0128@tmmu.edu.cn Hongli Zhou, Clinical Medical Research Center, The Second Affiliated Hospital, Army Medical University, No. 83 Xinqiao Main Street, Shapingba District, Chongqing, 400037, People’s Republic of China, Email zhouhongli@tmmu.edu.cnBackground: Inflammatory bowel disease (IBD) comprises a group of autoimmune disorders characterized by chronicity and resistance to cure, with an unknown etiology. …”
    Get full text
    Article
  16. 656

    Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis by Jinchen Chong, Zepeng Chen, Jiaze Ma, Linhai He, Yijia Zhu, Zhihua Lu, Zhengxi Qiu, Chen Chen, Yugen Chen, Feng Jiang

    Published 2025-02-01
    “…Abstract Background Ulcerative colitis (UC) is a type of inflammatory bowel disease, and current treatments often fall short, necessitating new therapeutic options. …”
    Get full text
    Article
  17. 657

    Guidance for the gastrointestinal evaluation and management of iron deficiency in Sub-Saharan Africa by W M Simmonds, Y Awuku, C Barrett, M Brand, K Davidson, D Epstein, E Fredericks, S Gabriel, S Grobler, C Gounden, L Katsidzira, V J Louw, V Naidoo, C Noel, E Ogutu, N Ramonate, N Seabi, M Setshedi, J Van Zyl, G Watermeyer, C Kassianides

    Published 2024-02-01
    “…The recommendations incorporate six areas, namely: general recommendations and practice, Helicobacter pylori, coeliac disease, suspected small bowel bleeding, inflammatory bowel disease, and preoperative care. Implementation of the recommendations is aimed at various levels from individual practitioners to healthcare institutions, departments and regional, district, provincial and national platforms. …”
    Get full text
    Article
  18. 658
  19. 659

    Systematic identification of secondary bile acid production genes in global microbiome by Yuwei Yang, Wenxing Gao, Ruixin Zhu, Liwen Tao, Wanning Chen, Xinyue Zhu, Mengping Shen, Tingjun Xu, Tingting Zhao, Xiaobai Zhang, Lixin Zhu, Na Jiao

    Published 2025-01-01
    “…Furthermore, we highlighted the associations between secondary bile acids (SBAs) and gastrointestinal and hepatic disorders, including inflammatory bowel disease (IBD), colorectal cancer (CRC), and nonalcoholic fatty liver disease (NAFLD), further elucidating disease-specific alterations in secondary bile acid production genes. …”
    Get full text
    Article
  20. 660

    Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and i... by Sofia Ramiro, Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Lianne S Gensler, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Tetsuya Tomita, Carmen Fleurinck, Ute Massow, Thomas Vaux

    Published 2025-01-01
    “…EAIR of serious infections was 1.4; no active tuberculosis was reported. Active inflammatory bowel disease and anterior uveitis EAIRs were 0.8 and 0.7, respectively. 202/303 (66.7%) patients completed Week 256. 42 (13.9%) patients discontinued treatment due to TEAEs.Efficacy at Week 48 was maintained for 5 years. …”
    Get full text
    Article